Literature DB >> 19753472

Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina.

Sergio Sosa-Estani1, Rodolfo Viotti, Elsa Leonor Segura.   

Abstract

The purpose of this review is to describe research findings regarding chronic Chagas disease in Argentina that have changed the standards of care for patients with Trypanosoma cruzi infection. Indirect techniques (serological tests) are still the main tools for the primary diagnosis of infection in the chronic phase, but polymerase chain reaction has been shown to be promising. The prognosis of patients with heart failure or advanced stages of chagasic cardiomyopathy is poor, but a timely diagnosis during the initial stages of the disease would allow for prescription of appropriate therapies to offer a better quality of life. Treatment of T. cruzi infection is beneficial as secondary prevention to successfully cure the infection or to delay, reduce or prevent the progression to disease and as primary disease prevention by breaking the chain of transmission. Current recommendations have placed the bulk of the diagnostic and treatment responsibility on the Primary Health Care System. Overall, the current research priorities with respect to Chagas disease should be targeted towards (i) the production of new drugs that would provide a shorter treatment course with fewer side effects; (ii) the development of new tools to confirm cure after a full course of treatment during the chronic phase and (iii) biomarkers to identify patients with a high risk of developing diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19753472     DOI: 10.1590/s0074-02762009000900023

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  31 in total

1.  Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.

Authors:  Denise da Gama Jaén Batista; Marcos Meuser Batista; Gabriel Melo de Oliveira; Patrícia Borges do Amaral; Joseli Lannes-Vieira; Constança Carvalho Britto; Angela Junqueira; Marli Maria Lima; Alvaro José Romanha; Policarpo Ademar Sales Junior; Chad E Stephens; David W Boykin; Maria de Nazaré Correia Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Clinical aspects of Chagas disease and implications for novel therapies.

Authors:  Cristiane Menezes; Germano Carneiro Costa; Kenneth J Gollob; Walderez O Dutra
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

Review 3.  Parasitic infections and myositis.

Authors:  Samar N El-Beshbishi; Nairmen N Ahmed; Samar H Mostafa; Goman A El-Ganainy
Journal:  Parasitol Res       Date:  2011-09-01       Impact factor: 2.289

4.  A systems approach to vaccine decision making.

Authors:  Bruce Y Lee; Leslie E Mueller; Carla G Tilchin
Journal:  Vaccine       Date:  2016-12-22       Impact factor: 3.641

5.  Lack of association between blood-based detection of Trypanosoma cruzi DNA and cardiac involvement in a non-endemic area.

Authors:  F F Norman; A Pérez-Ayala; J A Pérez-Molina; M Flores-Chavez; C Cañavate; R López-Vélez
Journal:  Ann Trop Med Parasitol       Date:  2011-09

6.  Putative Role of the Aldo-Keto Reductase from Trypanosoma cruzi in Benznidazole Metabolism.

Authors:  Patricia Andrea Garavaglia; Marc Laverrière; Joaquín J B Cannata; Gabriela Andrea García
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

7.  New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients.

Authors:  María Gabriela Álvarez; Yolanda Hernández; Graciela Bertocchi; Marisa Fernández; Bruno Lococo; Juan Carlos Ramírez; Carolina Cura; Constanza Lopez Albizu; Alejandro Schijman; Marcelo Abril; Sergio Sosa-Estani; Rodolfo Viotti
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

8.  Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.

Authors:  D E Perez-Mazliah; M G Alvarez; G Cooley; B E Lococo; G Bertocchi; M Petti; M C Albareda; A H Armenti; R L Tarleton; S A Laucella; R Viotti
Journal:  J Antimicrob Chemother       Date:  2012-10-26       Impact factor: 5.790

9.  Multicenter epidemiological and clinical study on imported Chagas diseases in Alicante, Spain.

Authors:  José M Ramos; Diego Torrús; Concepción Amador; Francisco Jover; Fabiola Pérez-Chacón; Yamileth Ponce; Francisco J Arjona; Elena Caro; Concepción Martínez-Peinado; Ingrid Gallegos; José M Cuadrado; Antonio Tello; Felix Gutiérrez
Journal:  Pathog Glob Health       Date:  2012-10       Impact factor: 2.894

10.  Towards a paradigm shift in the treatment of chronic Chagas disease.

Authors:  R Viotti; B Alarcón de Noya; T Araujo-Jorge; M J Grijalva; F Guhl; M C López; J M Ramsey; I Ribeiro; A G Schijman; S Sosa-Estani; F Torrico; J Gascon
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.